De novo growth

Lonally, the templates were chosen by trial and error or exhaustive enumeration. A itafional method named ZEBEDDE (ZEolites By Evolutionary De novo DEsign) en developed to try to introduce some rationale into the selection of templates et al. 1996 Willock et al. 1997]. The templates are grown within the zeolite by an iterative inside-out approach, starting from a seed molecule. At each jn an action is randomly selected from a list that includes the addition of new (from a library of fragments), random translation or rotation, random bond rota-ing formation or energy minimisation of the template. A cost function based on erlap of van der Waals spheres is used to control the growth of the template ale ... 

Cyanobacteria, prokaryotic algae that perform oxygenic photosynthesis, respond to a decrease in ambient growth temperature by desaturating the fatty acids of membrane lipids to compensate for the decrease in the molecular motion of the membrane lipids at low temperatures. During low-temperature acclimation of cyanobacterial cells, the desaturation of fatty acids occurs without de novo synthesis of fatty acids [110, 111]. All known cyanobacterial desaturases are intrinsic membrane proteins that act on acyl-Hpid substrates. 

T. brucei is unable to synthesize purines de novo and, as such, is dependent upon salvage mechanisms from the host. A number of transporters and enzymes are used by T. brucei to accomplish this task, and inhibition of these targets offers promise for development of trypanocides [39]. This strategy has been validated by demonstration that cordycepin (34), a substrate for T. brucei adenosine kinase (TbAK), which terminates RNA synthesis and parasite growth, can cure stage 2 HAT infections in mice when coadministered with deoxycoformycin (35), an adenosine deaminase inhibitor [40]. 

The effect of 6-mercaptopurine on the incorporation of a number of C-labelled compounds into soluble purine nucleotides and into RNA and DNA has been studied in leukemia L1210, Ehrlich ascites carcinoma, and solid sarcoma 180. At a level of 6-mercaptopurine that markedly inhibited the incorporation of formate and glycine, the utilization of adenine or 2-aminoadenine was not affected. There was no inhibition of the incorporation of 5(or 4)-aminoimidazole-4(5)-carboxamide (AIC) into adenine derivatives and no marked or consistent inhibition of its incorporation into guanine derivatives. The conversion of AIC to purines in ascites cells was not inhibited at levels of 6-mercaptopurine 8-20 times those that produced 50 per cent or greater inhibition of de novo synthesis [292]. Furthermore, AIC reverses the inhibition of growth of S180 cells (AH/5) in culture by 6-mercaptopurine [293]. These results suggest that in all these systems, in vitro and in vivo, the principal site at which 6-mercaptopurine inhibits nucleic acid biosynthesis is prior to the formation of AIC, and that the interconversion of purine ribonucleotides (see below) is not the primary site of action [292]. Presumably, this early step is the conversion of PRPP to 5-phosphoribosylamine inhibited allosterically by 6-mercaptopurine ribonucleotide (feedback inhibition is not observed in cells that cannot convert 6-mercaptopurine to its ribonucleotide [244]. 

Leflunomide is a prodrug that is converted to an active malonitrilamide metabolite, A77 1726 (Ml). Ml inhibits T-cell proliferation by blocking de novo pyrimidine synthesis and inhibiting the tyrosine kinases that are associated with certain cytokine and growth factor receptors. 

Figure 10.11 The use of ferritin as a label for the mechanism of growth of vesicles (adapted from Berclaz et al, 2001a b). Schematic representation of the possible vesicle formation and transformation processes when oleate, and oleic acid, are added to pre-formed vesicles which have been labelled, (a) The situation if only de novo vesicle formation occurs, (b) Growth in size of the pre-formed and labeled vesicles which may lead to division, either yielding vesicles that all contain marker molecules (case i, a statistical redistribution of the ferritin molecules) or also yielding vesicles that do not contain markers (case ii). Compare all this with Figure 10.9.

---